Compare SFWL & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFWL | QTTB |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.7M | 80.0M |
| IPO Year | 2021 | 2018 |
| Metric | SFWL | QTTB |
|---|---|---|
| Price | $0.90 | $5.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 5.9K | ★ 302.6K |
| Earning Date | 03-27-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.06 | ★ $2.28 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.40 |
| 52 Week High | $1.29 | $8.05 |
| Indicator | SFWL | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 45.08 |
| Support Level | $0.85 | $3.75 |
| Resistance Level | $1.01 | $7.69 |
| Average True Range (ATR) | 0.03 | 0.64 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 10.50 | 28.86 |
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The company's operations are based in the PRC. Its integrated logistics solutions are comprised of three business streams: B2B freight transportation services; cloud storage services; and value-added services. The company derives maximum revenue from Transportation, followed by Warehouse storage management services. The solutions provides by the company are : Internet TV; Electronic communication; Textiles and Apparel; Automotive parts; and e-commerce.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).